PHILADELPHIA, PA – August 31, 2023 – Strados Labs is thrilled to announce its selection as a quarterfinalist for the prestigious 2023 Digital Health Awards, presented by the Digital Health Hub Foundation. Strados Labs was chosen as a quarterfinalist for the Best in Class in the Pediatric-Adolescent Care Innovation Health category.
This recognition highlights the company’s dedication to improving disease management for Pediatric Asthma, which affects more than 5 million children each year. The Digital Health Awards celebrate organizations that demonstrate excellence in leveraging digital advancements to enhance healthcare services and patient outcomes. As a quarterfinalist, Strados Labs stands out for its innovative technology, the RESP Biosensor, which is used to objectively capture lung sounds for early symptoms of asthma exacerbation such as coughing and wheezing.
“After being recognized by the Digital Health Awards last year as a Rising Star, we are thrilled to return this year as a Best in Class company in the Pediatric/Adolescent category” Says Nick Delmonico, CEO & Cofounder at Strados Labs.
Out of a substantial pool of over 1,500 submissions, only the most promising 16 quarterfinalists per category, per track have advanced to this stage.
“This year has been our most competitive yet as we’ve received a great surge in submissions, numbering in the thousands, pouring in from companies around the world. We are so impressed by the pioneering work in digital health happening on a global scale. Congratulations to all of our quarterfinalists on their notable success.” – Mark Goldstein, Chairman of Digital Health Hub Foundation.
Finalists will be announced September 22, 2023 and the winners will be announced at the Grand Finale taking place at HLTH on the Moon Stage on October 9, 2023.
About Strados Labs
Strados Labs is a medical technology company specializing in the enhancement of respiratory disease management. Utilizing advanced biosensors and machine learning algorithms, the company provides real-time monitoring of lung health. Strados Labs’ FDA-cleared RESP Biosensor empowers clinicians to remotely detect changes in lung sound symptoms such as cough and wheeze that can indicate exacerbations, allowing for earlier interventions. In addition to its clinical applications, the RESP Biosensor is employed in life sciences research to assess the effectiveness of treatments in clinical trials. Strados Labs is privately owned and based in Philadelphia, PA.
For more information, visit Stradoslabs.com or follow us on LinkedIn and Twitter.
Media Contact:
Gabe Steerman
215-906-5538
gabe@stradoslabs.com
www.stradoslabs.com